Multiple Myeloma Clinical Trial

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Summary

RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers.

PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.

View Full Description

Full Description

OBJECTIVES:

Identify the specific molecular function of the Fanconi anemia (FA) complementing gene products in hematopoietic progenitor cells from patients and normal volunteers.
Identify functional defects in hematopoietic stromal cells, including macrophages, from patients with FA, and selected blood cancers as well as normal volunteers.

OUTLINE: Peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts are collected for loss-of-function and gain-of-function analysis related to the Fanconi anemia complementing gene.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Meets 1 of the following criteria:

Diagnosis of one of the following:

Fanconi's anemia requiring bone marrow biopsy as part of standard care (adults and children)
Myeloproliferative disorder or myeloma (adults)

Healthy volunteer, meeting 1 of the following criteria:

Over 18 years of age
Bone marrow transplant donor (children)

PATIENT CHARACTERISTICS:

Hemoglobin > 13 g/dL
White blood cells (WBC) > 4,000/mm³
Platelet count > 150,000/mm³
No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or fungal)
No known blood abnormality (healthy volunteers)
No allergies to lidocaine or xylocaine

PRIOR CONCURRENT THERAPY:

Not specified

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

213

Study ID:

NCT00900055

Recruitment Status:

Completed

Sponsor:

OHSU Knight Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Knight Cancer Institute at Oregon Health and Science University
Portland Oregon, 97239, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

213

Study ID:

NCT00900055

Recruitment Status:

Completed

Sponsor:


OHSU Knight Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.